Cargando…

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

OBJECTIVES: To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs). METHODS: In this 24-week multicentre, placebo-controlle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feist, Eugen, Fatenejad, Saeed, Grishin, Sergey, Korneva, Elena, Luggen, Michael E, Nasonov, Evgeniy, Samsonov, Mikhail, Smolen, Josef S, Fleischmann, Roy M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664111/ https://www.ncbi.nlm.nih.gov/pubmed/36109142 http://dx.doi.org/10.1136/ard-2022-222630

Ejemplares similares

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
por: Nasonov, Evgeniy, et al.
Publicado: (2022)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Genovese, Mark C., et al.
Publicado: (2016)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
por: Kaeley, Gurjit S., et al.
Publicado: (2016)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study
por: Genovese, Mark C., et al.
Publicado: (2018)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Robinson, Michael F., et al.
Publicado: (2020)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment
por: Taylor, Peter C, et al.
Publicado: (2018)

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study
por: Daien, Claire, et al.
Publicado: (2022)

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis
por: Sauer, Brian C., et al.
Publicado: (2017)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
por: Kremer, Joel M., et al.
Publicado: (2016)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
por: Calabrese, Leonard H., et al.
Publicado: (2020)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate‐Treated Early Rheumatoid Arthritis Patients
por: Lourdudoss, Cecilia, et al.
Publicado: (2018)

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
por: Choy, Ernest, et al.
Publicado: (2019)

Development and validation of a methotrexate adherence assay
por: Bluett, James, et al.
Publicado: (2019)

Methotrexate in pregnancy: still many unanswered questions
por: Weber-Schoendorfer, Corinna, et al.
Publicado: (2023)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
por: Matsubara, Tsukasa, et al.
Publicado: (2018)

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
por: Chatzidionysiou, Katerina, et al.
Publicado: (2019)

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study
por: Takahashi, Chihiro, et al.
Publicado: (2017)

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
por: Fleischmann, Roy M, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2016)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i5tu9k7cujorh4dse9q88cclcj